News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biolight Added To The TA-Biomed And The TA-Bluetech Indices On The TASE


6/16/2014 7:48:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel, June 16, 2014 /PRNewswire via COMTEX/ -- TEL AVIV, Israel, June 16, 2014 /PRNewswire/ --

BioLight Life Sciences Investments Ltd. (tase:BOLT) /quotes/zigman/27898216/delayed/quotes/nls/blgty BLGTY 0.00% , a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announced today that it has been notified by the Tel Aviv Stock Exchange that BioLight will be included in the Tel Aviv Biomed Index (TA-Biomed) and also in the Tel Aviv BlueTech index (TA- BlueTech), effective June 15, 2014. The TA-Biomed tracks leading Biomed shares mainly based on the size of market capitalization and market float of the Biomed sector stocks that are traded on the Exchange. TA-BlueTech tracks leading shares mainly based on market capitalization of the Technology and Biomed sectors in the Exchange. Both indices serve as an underlying asset for financial vehicles, such as Index-Linked Certificates that are traded on the Exchange and indexed mutual funds.

"We are pleased to have our shares included in both the TA-Biomed and TA-BlueTech, the Tel Aviv Stock Exchange's most closely-tracked indices for Tech and Biomed companies shares," said Suzana Nahum-Zilberberg, BioLight's chief executive officer. "Joining the highly ranked companies on the Israeli Stock Exchange reflects BioLight's continued success and the recognition it receives from the capital markets."

About BioLight

BioLight Life Sciences Investments invests in, manages and commercializes biomedical innovations grouped into "clusters" around defined medical conditions. Its two current clusters are in ophthalmology via 100% ownership of XLVision Sciences and in cancer diagnostics via a 29% controlling ownership of Micromedic (tase:MCTC). XLVision technologies include IOPtiMate™, a laser-based noninvasive surgical treatment for glaucoma; TeaRx, a point-of-care dry-eye syndrome diagnostic test; and Eye-D™, a long-term controlled release drug-delivery implant platform. Micromedic diagnostic tests are designed to detect colorectal, cervical, breast, bladder, lung and other cancers. Leading key investors, holding about 45% of BioLight's shares, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India's largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel.

For more information please visit the Company's website at www.bio-light.co.il .

CONTACTS:

BioLight Itai Bar-Natan, CFO ( itai@bio-light.co.il ) Tel: +972-73-2753400

LHA Kim Sutton Golodetz ( kgolodetz@lhai.com ) +1-(212)-838-3777

Or

Bruce Voss ( bvoss@lhai.com ) +1-(310)-691-7100

SOURCE BioLight Life Sciences Investments Ltd

Copyright (C) 2014 PR Newswire. All rights reserved

Help employers find you! Check out all the jobs and post your resume.

Read at Market Watch

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES